On Monday, Shares of Gilead Sciences, Inc (NASDAQ:GILD), lost -4.44% to $100.65.
Gilead Sciences, declared that the company’s Marketing Authorization Application (MAA) for an investigational, once-daily single tablet regimen that combines emtricitabine 200 mg, tenofovir alafenamide 25 mg and rilpivirine 25 mg (R/F/TAF) has been fully validated and is now under evaluation by the European Medicines Agency (EMA). Emtricitabine and tenofovir alafenamide are marketed by Gilead Sciences and rilpivirine is marketed by Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
In addition to R/F/TAF, two other MAAs for TAF-based regimens are under review by the EMA. The MAA for an investigational, once-daily single tablet regimen containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg (E/C/F/TAF) was fully validated on December 23, 2014. The MAA for two doses of an investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (200/10 mg and 200/25 mg) (F/TAF) was fully validated on May 28, 2015. Gilead has presented New Drug Applications to the U.S. Food and Drug Administration for E/C/F/TAF, F/TAF and R/F/TAF on November 5, 2014, April 7, 2015, and July 1, 2015, respectively.
The R/F/TAF filing is the latest step in an expanded development and commercialization agreement between Gilead and Janssen, first established in 2009. Under this agreement, and pending the product’s approval, Gilead will be responsible for the manufacturing, registration, distribution and commercialization of the regimen in most countries, while Janssen will distribute it in about 17 markets and have co-detailing rights in several key markets. The original agreement was established for the development and commercialization of Eviplera®, marketed as Complera® in the United States.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. The company’s products comprise Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease.
Shares of Lowe’s Companies, Inc (NYSE:LOW), declined -3.94% to $68.31, during its last trading session.
The Board of Directors for Lowe’s Companies, Inc. (LOW) has declared a quarterly cash dividend of twenty eight cents ($0.28) per share, payable November 4, 2015, to shareholders of record as of October 21, 2015.
Lowe’s Companies, Inc. operates as a home improvement retailer. The company offers products for maintenance, repair, remodeling, and home decorating. It provides home improvement products under the categories of kitchens and appliances; lumber and building materials; tools and hardware; fashion fixtures; rough plumbing and electrical; lawn and garden; seasonal living; paint; home fashions; storage and cleaning; flooring; millwork; and outdoor power equipment.
Finally, GigOptix Inc (NYSEMKT:GIG), ended its last trade with 0.61% gain, and closed at $1.66.
GigOptix Inc, declared the pricing of its underwritten public offering of an aggregate of 9,218,000 newly issued shares of common stock at a price of $1.70 per share. The Company anticipates to receive gross proceeds of $15.67 million, before deducting underwriting discounts and other estimated offering expenses. The underwriters have also been granted a 30-day option to purchase up to 1,425,000 shares of common stock to cover over-allotments, if any. The net proceeds to the Company from the offering of its shares are predictable to be about $14.73 million after deduction of underwriting discounts and assuming no exercise of the underwriters’ over-allotment option. In addition, certain officers and directors as selling stockholders sold 282,000 shares of formerly issued shares of common stock in the underwritten public offering at a price of $1.70 per share. The Company is receiving none of the proceeds from the sale of shares by the selling stockholders. Subject to customary conditions, the offering is predictable to close on August 26, 2015.
The Company anticipates to use the net proceeds from the offering of the shares which it is selling, for potential acquisitions for planned growth, counting the acquisition of critical technologies and scalable businesses. The focus will be on multiple attractive global targets, counting entities that the company has been tracking for the last couple of years.
GigOptix, Inc. operates as a fabless supplier of semiconductor components that enable end-to-end information streaming over optical and wireless networks.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
